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Summary 
Using granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin 4 we have 
established  dendritic cell (DC) lines from blood mononuclear cells that maintain the antigen 
capturing and processing capacity characteristic  of immature dendritic cells in vivo. These cells 
have typical dendritic morphology, express high levels  of major histocompatibility  complex (MHC) 
class I and class II molecules, CD1, Fcq,  RII, CD40, B7, CD44, and ICAM-1, and lack CD14. 
Cultured DCs are highly stimulatory in mixed leukocyte reaction (MLR) and are also capable 
of triggering cord blood naive T  cells. Most strikingly, these DCs are as efficient as antigen- 
specific B cells in presenting tetanus toxoid (TT) to specific T  cell clones.  Their efficiency of 
antigen presentation can be further enhanced by specific antibodies via FoR-mediated antigen 
uptake. Incubation of these cultured DCs with tumor necrosis  factor o~ (TNF-o  0  or soluble 
CD40 ligand (CD40L) for 24 h results in an increased surface expression of MHC dass I and 
class II molecules, B7,  and ICAM-1 and in the appearance of the CD44 exon 9 splice variant 
(CD44-vg); by contrast, Fc'yRII is markedly and sometimes completely downregulated. The 
functional consequences of the short contact with TNF-c~ are an increased T  cell stimulatory 
capacity in MLR, but a 10-fold decrease in presentation of soluble TT and a 100-fold decrease 
in presentation of TT-immunoglobulin G  complexes. 
D 
endritic cells (DCs) 1 play a critical role in antigen pre- 
sentation in vivo (1). They exist in two stages of matu- 
ration. As immature cells, DCs are scattered throughout the 
body in nonlymphoid organs, where they appear to exert a 
sentinel function. They pick up and process antigen and sub- 
sequently move to the T-dependent areas of secondary lym- 
phoid organs. During this process of maturation, they lose 
antigen-capturing capacity and become mature immunostimu- 
latory DCs that trigger naive T  cells recirculating through 
these areas (2,  3). 
A similar maturation process occurs spontaneously when 
Langerhans cells (LCs, which represent immature DCs in skin) 
are cultured in vitro (4, 5). Under these conditions LCs rap- 
idly lose the capacity to pick up and process soluble antigen, 
but acquire high T  cell costimulatory capacity. Thus, both 
in vivo and in vitro studies suggest that antigen capture/pro- 
1  Abbreviations used in this paper: CD40L, CD40 ligand; DCs, dendritic 
cells; Ii, invariant chain; LCs, Langerhans cells; TT, tetanus  toxoid. 
cessing and immunostimulation are the property of DCs at 
different stages of maturation. 
The mechanism of antigen uptake determines the efficiency 
of presentation of soluble antigens on class II molecules (6). 
The pinocytic activity of DCs has been reported to be at least 
as high as that of other APCs (7). In addition, splenic DCs 
and LCs express FeyRII, which is lost when these cells ma- 
ture in vitro (4, 8). Although DCs are able to present soluble 
antigen (5, 9-11),  their efficiency has not been compared to 
that of other APCs. A general consensus has emerged that 
DCs may actually be rather inefficient in presenting soluble 
antigens and it has been argued that, for this reason, efficient 
presentation in vivo may be an exclusive property of antigen- 
specific B cells (12). 
A common progenitor for granulocytes, macrophages, and 
DCs has been identified in mouse  bone marrow (13) as a MHC 
class II negative cell that can develop into the three different 
myeloid pathways under the aegis of GM-CSF.  Proliferating 
precursors  of DCs that can be expanded into DC lines in 
vitro with GM-CSF are present both in mouse bone marrow 
(14) and peripheral blood (15). To date, human DC lines have 
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cord blood (16) or bone marrow (17) using a combination 
of GM-CSF and TNF-oL. 
There are several reasons for wishing to establish in vitro 
cultures  of immature  DCs.  First,  to exploit  their antigen- 
presenting capacity; second to compare them with other APCs 
for this function; third, to identify the signals that modulate 
antigen capturing and presenting function. Here we describe 
a method to culture DCs from human peripheral blood, such 
that the phenotypic and functional characteristics of imma- 
ture DCs are retained.  These cells are indeed as effident as 
antigen-specific B calls and can use Fc3,RII to further increase 
uptake of antigen in antigen-antibody complexes. Matura- 
tion of these cells can be induced by TNF-cz,  resulting  in 
upregulation  of their capacity to stimulate naive allogeneic 
T cells and downregnlation of their capacity to present soluble 
antigen. 
Materials  and Methods 
Media and Reagents.  The medium used throughout was RPMI 
1640 supplemented with 2 mM t-glutamine, 1% nonessential amino 
acids, 1%  pyruvate, 50 #g/ml  kanamycin, 5  x  10 -s M  2-ME 
(Gibco Laboratories, Grand Island, NY) and 10% FCS (Hyclone 
Laboratories, Inc., Logan, UT). Tetanus toxoid (TT) was purchased 
from Connaught Laboratories, Ltd. (Wtlowdale, Ontario, Canada). 
Human anti-TT antibodies (all IgG) were purified by chromatog- 
raphy on protein A-Sepharose from concentrated culture supema- 
tants of EBV-B cell clones (18). Human recombinant  II.-2, IL-4, 
and GM-CSF were produced in our laboratory by PCR cloning 
and expression in the myeloma expression system described by 
Traunecker et al. (19). The concentration of IL,4 and GM-CSF were 
determined using commercial ELISA assays. Purified human recom- 
binant GM-CSF and TNF-c~ were a generous gift of Dr. Manfred 
Brockhaus (Hoffmann-La Roche, Basel, Switzerland).  A soluble 
chimeric fusion protein between the mouse CD8 cx-chain and the 
human  CD40 ligand (CD40L) was a generous gift of Dr.  Peter 
Lane (Basel Institute for Immunology) (20). 
Culture of DCs frora Peripheral  Blood.  PBMC were isolated on 
lymphoprep cushions (LSM; Organon Teknilra Corp.,  Rockville, 
MD) resuspended in ILPMI-10% FCS, and allowgd to adhere to 
6-well plates (Costar Corp., Cambridge, MA). After 2 h at 37~ 
the nonadherent  cells were removed and the adherent cells were 
detached by incubation with Mg  z+ and Ca  2+ free PBS containing 
0.5 mM EDTA at 37~  as described (21). In some experiments, 
PBMCs were separated on multistep Percoll gradients (Pharmacia 
Fine Chemicals, Uppsala, Sweden) and the light density fraction 
from  the  42.5-50%  interface  was  recovered and  depleted  of 
CD19 +  B  and  CD2 +  T  lymphocytes  using  magnetic  beads 
(Dynal, Oslo,  Norway).  The adherent or light density fractions 
were cultured  at 3  x  10S/ml in RPMI-10% FCS supplemented 
with 50 ng/ml GM-CSF and 1,000 U/ml IL-4. 
FACS |  Analysis,  Cell  staining  was performed  using  mouse 
monoclonal antibodies followed by FITC- or PE-conjugated ~fl~nity 
purified, isotype-sped~ goat anti-mouse antibodies (Southern Bio- 
technology  Associates, Birmingham,  AL). The following mAbs 
were used: L243 (IgG2a, antioDK),  W6/32 (IgG2a, anti-MHC 
class I); 32.2 (IgG1, anti-Fc~/RI), AT10 (IgG1, anti-Fc3,RII), OKT3 
(IgG2a, anti-CD3)  (all from the American Type Culture Collec- 
tion, Rockville, Maryland); SPVL3 (IgG2a, anti-DQ, provided by 
Dr.  H.  Spits, DNAX,  Palo Alto,  CA); B7.21 (IgG1,  anti-DP, 
provided by Dr. J. Trownsdale, ICRF, London, UK); BU45 [IgG1, 
anti-invariant chain (Ii); provided by Dr. N. Koch, Institute of Im- 
munology and Genetics, DKF2, Heidelberg, Germany]; NA1/34 
(IgG2a, anti-CDla),  WM25 (IgG1, anti-CDlb),  IOC3 (IgG1, anti- 
CDlc) (all provided by Dr.  F. Calabi,  Hammersmith  Hospital, 
London, UK); B7.24 (IgG2a, anti-B7; provided by Dr. Mark De- 
boer,  Immunogenetics,  Ghent,  Belgium);  RR1/1  (IgG1,  anti- 
ICAM-1), TS1/22 (IgG, anti-LFA1), TS2/9 (IgG1, anti-LFA3) (all 
provided by Dr. T. Springer, Harvard Medical School, Boston, MA); 
Leu 11a (IgG1, anti-CD16), Leu M3 (IgG2b, anti-CD14), Leu M5 
(IgG2b, anti-CD11c), Leu M9 (IgG1, anti-CD33),  Leu 11c (IgG1, 
anti-Fc3~RIII) (Becton Dickinson  & Co., Mountain  View, CA); 
25.34 (IgG, anti-CD44),  11.24 (IgG1, anti CD44-v9) (all provided 
by Dr. C. Mackay, Basel Institute for Immunology);  G28.5 (IgG1, 
anti-CD40, provided by Dr. A. E. Clark, University of Washington, 
Seattle, WA); HD37 (IgG1, anti-CD19;  Boehringer Mannheim, 
Mannheim, Germany). The samples were analyzed on a FACScan  | 
(Becton Dickinson) using propidium iodide to exclude dead cells. 
MLR.  1.5  x  10  s responding cells either from allogeneic adult 
PBMCs or cord blood (allogeneic MLR) or autologous  PBMCs 
(antologous MLR) were cultured  in 96 flat-bottom  microplates 
(Costar Corp.) with different numbers of irradiated (3,000 rad from 
a ~37Cs source) stimulator cells (DC or PBMC). Thymidine incor- 
poration was measured on day 5 by a 16-h pulse with [3H]thymi- 
dine (1 #Ci/well, sp act, 5 Ci/mMol; Amersham Life Science, Buck- 
ingham,  UK). 
Antigen Presentation  Assays.  TT-specific EBV-B cell clones and 
TT-specific T cell clones were isolated and maintained as previously 
described (18). T cell clone ASl1.15 recognizes a TT determinant 
corresponding  to residues 947-967  in association with DP4. To 
measure the efficiency of presentation  of a soluble antigen,  2  x 
103 TT-specific T cells were cultured with 5  x  103 cultured DCs 
(3,000 tad), 2  x  104 irradiated autologous EBV-B cells (6,000 tad) 
or 10  s autologous PBMCs (3,000 tad) in the presence of different 
concentrations  of TT in 200 #1 RPMI-10% FCS in flat-bottom 
microplates. The cultures were set up in the presence or absence 
of a fixed concentration  of a mixture of six different anti-TT IgG 
antibodies  (0.5 #g/ml each). [3H]Thymidine incorporation  was 
measured after 48 h. TT and anti-TT antibodies were allowed to 
react for 1 h before the addition  of APCs and T cells. In some 
experiments,  total PBMCs (1.5  x  10  s) or polyclonal short-term 
TT-specific T cell lines (2  x  104) were used as a source of TT- 
specific cells. [3H]Thymidine incorporation was measured on days 
5 and 2, respectively. 
Results 
Culture Conditions  for the Generation of DCs with Antigen- 
presenting Capacity.  Adherent cells or the light density Per- 
coll fraction from PBMCs were depleted of T  and B cells 
and cultured in RPMI-FCS supplemented with various com- 
binations ofGM-CSF, IL-4, and TNF-o~. The cell yields, sur- 
face phenotype and functional properties of cells grown with 
different cytokine combinations are shown in Table 1. It is 
evident that  a combination of GM-CSF and IL-4 provided 
the best conditions for the generation of cells with the char- 
acteristic phenotype and functional properties of DCs (high 
expression of CD1, class II and B7, and high stimulatory ca- 
pacity in allogeneic and autologous MLR). Furthermore cells 
from GM-CSF  +  IL-4-dependent  cultures were the most 
efficient at presenting soluble antigen TT to specific T  cell 
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TNF-o~ (16) were inferior to those obtained with GM-CSF 
+  IL-4, especially for presentation of soluble antigen. We 
therefore used DCs from GM-CSF  +  IL-4-dependent cul- 
ture in subsequent experiments. 
In a typical experiment, after '~7 d of culture with GM- 
CSF  +  IL-4, 50-80% of the cells appear as loosely adherent 
dumps or isolated floating cells with the typical dendritic 
morphology (see an example in Fig.  1) and motility, as as- 
sessed by time lapse videorecording (data not shown). Anal- 
ysis of surface markers (Table 1 and Fig. 2) showed that the 
large cells were homogeneous and expressed high levels of 
MHC class I and class II molecules, CDla, CDlb and CDlc, 
Fc'yRII, ICAM-1, CDllb,  CDllc,  CD40,  B7,  and CD33. 
CD14 was either low or negative in different preparations. 
Furthermore, DCs were positive for Ii, LFA-1,  LFA-3,  and 
CD44 and negative for Fc3'KI and FcyRIII (see also Table 
2).  Anti-CD3 and anti-CD19  antibodies were always used 
as control and found negative. Cell growth rapidly slowed 
down after the first 3-4 wk, but viable cells could be main- 
tained in culture with occasional feeding for up to 3  too. 
Stimulatory Capacity of DCs.  Cultured DCs were com- 
pared with PBMCs for their capacity to stimulate alloreac- 
tive T cells. Different numbers of DCs or PBMCs from the 
same donor were cultured with a fixed number of allogeneic 
T cells. Fig. 3 a shows that as few as 50 DCs could trigger 
a substantial response; on a per cell basis, DCs were 300-fold 
more effective than PBMCs in stimulating adult T  cells. It 
is interesting to note that only DCs but not PBMCs could 
trigger cord blood T  cells (Fig.  3 b). The observation that 
cord blood T cells, which are entirely naive, could be stimu- 
lated only by DCs underlines the specialized role of DCs for 
T  cell priming. 
Efficient  Presentation  of  Soluble Antigen and Antigen-Antibody 
Complexes by Immature DCs.  To evaluate the capacity of DCs 
to present a soluble antigen, we compared DCs,  PBMCs, 
and antigen-specific B cells for their capacity to present TT 
to a TT-specific T  cell clone. To evaluate the possible effect 
of Fc,/R in enhancing capture of antigen-antibody complexes, 
the cultures were set up in the presence or absence of a fixed 
concentration of anti-TT  IgG antibodies. 
As evident from Fig.  4, the efficiency of presentation, as 
measured from the TT concentration necessary to give 50% 
of maximum response, varies with the type of APC. DCs 
(Fig.  4 a) were the most effective APCs,  since  they could 
present TT  at a concentration of 10-10 M,  while PBMCs 
(Fig.  4 b) and nonspecific B cells (Fig.  4 c) required antigen 
concentrations higher than  10 -s  M.  Furthermore,  in  the 
presence of anti-TT antibodies,  the efficiency of  DCs increased 
at least 100-fold and a significant proliferative response was 
Figure  1.  Typical appearance of DC cultures  on day 15. 
1111  Sallusto  and Lanzavecchia Table  1.  Cell Yield, Surface Phenotype, Stimulator),, and Antigen-presenting Capacity of Light Density Mononuclear Cells Cultured with 
Various Cytokine Combinations 
GM-CSF  GM-CSF 
Alone  GM-CSF  IL-4  TNF-c~  TNF-~  IL-4 
Cell yield (%)* 
Day 4  23  68  23  43  57  84 
Day 8  6  114  25  46  74  99 
Day 20  2  152  14  64  90  125 
Surface markers 
CDla  ....  _+  + 
CDlb  -  _+  -  -  _+  + 
CDlc  ....  _+  + 
DR  ++  ++  ++  ++  ++  ++ 
DQ  -  -  +  -  +  + 
Class I  ++  ++  ++  ++  ++  ++ 
Fc~/RII  + +  +  + +  + +  +  + 
B7  -  _+  -  +  +  + 
CD40  -  + +  +  +  + +  + + 
CDllc  +  + +  + +  +  + +  + + 
ICAM-1  +  + +  +  + +  + +  + + 
CD14  +  _+  _+  +  -  - 
Stimulation and antigen presentationl 
Aliogeneic MLR* 
Maximum response  nd  32  +  21  40.9 _+ 2.7  33.4  _+ 1.7 
No.  cells for 50%  response  6,000  4,000  12,000 
Autologous MLR* 
Maximum response  nd  <1  <1  <1 
TT presentations 
Maximum response  nd  89.4 _+ 4.5  nd  nd 
ng/ml TT 50%  response  100 
53.1  _+ 3  68.1 _+ 2.2 
3,000  600 
<1  10.1  _+  2 
8.2  _+ 2.1  134.6  _+ 4 
>104  10 
* Cell yield at days 4,  8, and 20 expressed as percent of imput cells. 
The various cell populations were tested on day 8 for their capacity to stimulate in allogeneic and autologous  MLR. The maximum response and 
the number of cells required for stimulating 50% of the maximum response are shown. 
s 5  x  103 cells from the various cell populations were tested on day 10 for thdr capacity to present different concentrations  of TT to a TT-spectic 
T cell done. The maximum response and the concentration of TT required for stimuhting 50% of the maximum response are shown. 
Icpm  x  10-3+SD. 
obtained at TT concentrations of 10-t4 M. When compared 
with PBMCs, DCs were at least 100-fold more efficient, both 
in the absence and in the presence of anti-TT antibody (Fig. 
4  b). Finally, DCs were as efficient as some antigen-specific 
B  cells (Fig. 4  c) and, in the presence of soluble antibodies, 
appeared to be the most efficient APC for soluble antigens. 
We also compared DCs and PBMCs for their capacity to 
present TT  to autologous peripheral blood T  cells and to 
polyclonal short-term TT-specific lines. As evident from Fig. 
5, a  and b,  DCs  were  again more powerful than PBMCs, 
both in terms of maximum response and amount of TT re- 
quired. The shape of the dose-response curve may be due to 
the presence of T  cells with different sensitivities to antigen 
and thus may reflect the ability of DCs to stimulate a higher 
number of specific T  cells. 
Modulation of  Surface  Phenotype and Antigen-lnrsenting Function 
by CD40L and TNF~.  The above results indicated that DCs 
obtained from GM-CSF  +  IL-4 cultures shared many prop- 
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Figure 2.  Surface  phenotype of 
DCs at day 8 of culture. TM histo- 
grams show fluorescence  values on 
gated large cells. The amplification 
was set at a very low value (x400) 
to allow quantitative measurement 
of the extremely bright cells. The 
first panel shows  the control staining 
with isotype-matched  irrelevant an- 
tibody. 
100  - 
80- 
60- 
~40- 
20- 
60- 
40- 
E 
20- 
a 
........  i  ................  I 
0. l  1  10  100  1000 
............  i  1  ....  ~,,,i  ~,,  I  '  I  I  'i"i--  ............... 
0 . 1  1  l0  100  1000 
APC x  10  -3 
erties with immature DCs such as LCs, at least with respect 
to surface phenotype and presentation of soluble antigen. We 
therefore asked whether these cells might be induced to ma- 
ture  in culture  and whether  this  maturation  would affect 
antigen-presenting  capacity. 
We tested the effect of TNF-ot and CD40L, which repre- 
sent two effector molecules of natural  and acquired immu- 
nity. As shown in Table 2, DCs underwent a rapid change 
in surface phenotype upon incubation with TNF-a or CD40L. 
By 24 h, surface MHC class I and class II molecules increased 
two- -threefold, while Ii expression was reduced by approxi- 
mately half.  ICAM-1 expression also increased,  a fact that 
was presumably responsible for the spontaneous cell aggre- 
gation observed. B7 and CD40 were also upregulated, whereas 
FcyRII was rapidly and sometimes completely dowuregu- 
lated. Interestingly, treatment with TNF-ot increased CD44 
expression and induced the appearance of a new splice variant 
carrying  exon 9  (22). 
Some of these changes resemble those occurring in vivo 
when LCs move from skin to lymph nodes (4). We therefore 
asked what  consequence these changes might  have on the 
capacity of DCs to stimulate T  cells and to present soluble 
Figure 3.  Cultured DCs are highly stimulatory in MLK and are the 
only cells  capable  of triggering cord blood T cells. Adult peripheral blood 
(a) or cord blood  mononuclear (b) cells  were  cultured  with different  numbers 
of allogeneic PBMCs (@, m) or DCs (O, D) from the same donor. The 
proliferative response was measured on day 5. 
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Figure  4.  Cultured DCs are the most e~cient APCs for presentation 
of soluble antigen as such or complexed with IgG antibodies. The three 
panels  represent the proliferative  response of the same T cell  clone to different 
concentrations of TT in the presence or absence of a fixed concentration 
of anti-TT IgG antibodies and different irradiated APCs. (a): 5  x  10  3 DCs 
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antibody or a nonspecitic polyclonal line in the absence (A) or presence 
(A) of anti-TT antibody. Proliferative response was measured on day 2. 
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antigen. Pretreatment with TNF-c~ or CD40L increased two- 
-threefold the stimulatory  capacity in MLR (data not shown), 
a result that is consistent with the expression of higher levels 
of MHC products, adhesion, and costimulatory molecules. 
Remarkably,  the same  DCs  showed a reduced capacity  to 
present TT after treatment with TNF-ct (Fig.  6 a), being 
about 10-fold less efficient. Moreover, the enhanced presen- 
tation of immune complexes was completely abrogated,  con- 
comitant  with a downregulation  of Fc~RII  (Fig.  6  b). 
TNF-ct did not have cytotoxic effect on GM-CSF  +  IL- 
4-dependent  DCs and actually,  in some cases,  slightly en- 
hanced cell viability. However, the downregulation of Fc3,RII 
and the decrease in antigen-presenting capacity were irrevers- 
ible, since they were still present even several days after TNF-ct 
had been removed (data  not shown). 
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Figure  5.  Presentation of TT to polydonal T cells. Proliferative  response 
of peripheral blood T cells (a) or polydonal short-term TT-specific  T cell 
lines  (b)  to  different  concentrations  of TT  presented by  autologous 
mononuclear cells (O) or autologous DCs (D). Proliferative response was 
measured on days 5 and d 2, respectively. The backgrounds of the response 
without TT (autologous  MI, IL) were subtracted. 
Discussion 
The  availability  of immature  DCs  is  instrumental  for 
studying the mechanisms of antigen capture and processing 
by these cells,  as well as to identify signals  that modulate 
this function. In this study we have shown that it is possible 
to grow in vitro human cell lines with many of the charac- 
teristics  of immature DCs. The two most striking findings 
are the highly efficient presentation of soluble antigen by these 
cell lines, and their rapid response to TNF-a leading to up- 
regulation of adhesion and costimulatory  molecules and down- 
regulation  of antigen-capturing  and  -processing capacity. 
Our DC lines differ from those described by Caux et al. 
(16) in two important aspects: the use of adult PBMCs (23) 
rather than cord blood precursors and the use of IL-4 rather 
than TNF-c~. Indeed adult adherent cells grown with GM- 
CSF  +  TNF-ot have lower stimulator] capacity and are un- 
able to present soluble antigen (Table 1), a fact that can be 
explained by  the capacity  of TNF-ct  to regulate  antigen- 
presenting function (Fig. 6), Our DC lines were generated 
from adult peripheral blood and require IL-4 in addition to 
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TNF-~ or CD40L 
GM-CSF+IL4  +  TNF-c~*  +  CD40L* 
eq 
Second Ab  28s  33  30  -~ 
CDla  369  492  428 
O 
CDlb  200  423  270 
CDlc  295  454  377 
DR  1,555  2,938  2,117 
DQ  549  1,416  1,210 
DP  129  281  187 
Ii  245  185  126 
MHC class I  991  2,044  1,798 
Fc',/RII  1,684  737  862 
to 
B7  84  163  127  o  ~ 
CD40  673  1,612  742  "6 
CD11c  534  414  481  es 
ICAM-1  228  620  457  E  t- 
LFA-1  550  448  517 
LFA-3  219  290  252 
CD44  845  1,235  1,274 
CD44-v9  62  147  98 
CD14  75  40  40 
* DCs were incubated for 24 h with 10 ng/ml TNF-c~. 
t DCs were incubated for 24 h with CD40L-mouse CD8 at a saturat- 
ing concentration as determined by staining with anti-mouse CD8. 
S  Mean fluorescence  intensity. Comparable results were obtained  in four 
separate ~perlments. 
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Figure 6.  Treatment of cultured DCs with TNF-(x downregulates 
F~RII  and decreases antigen-capturing and -presenting capacity. (a) 
Proliferative  response of a TT-specific  T cell clone to different  concentra- 
tions of TT in the presence  of 5 x  103 irradiated DCs that have been 
pretreated with TNF-~ (O, @) or left untreated ([], all). The culture 
were set up in the absence (O, D) or in the presence  (@, II) of anti-TT 
IgG antibodies  as in Fig. 4. (b) surface  expression  of Fc'ytLII  on DCs that 
had been pretreated overnight with TNF-ot  or left in growth medium. 
GM-CSF to maintain the immature, antigen presentation com- 
petent state.  These conditions have been previously shown 
to increase CD1 expression on adherent cells (21,  24).  It is 
not clear what role IL-4 may play, but it is interesting to 
speculate it may antagonize the effect of TNF-c~ and other 
maturation-inducing signals. Whether IL-4 or other cytokines 
may play a physiological role in maintaining the immature 
DC pool in vivo is a matter of speculation. 
The identification of GM-CSF/IL-4-expanded cells as DCs 
was based on three well-established and accepted criteria (25, 
26): first, their typical morphology and motility; second, their 
surface phenotype, with high expression of CD1, MHC class 
I and class II, Ii, Fc3'RII, B7, CD40, ICAM-1, LFA-3, and 
CD11c; and third, their high stimulatory capacity for naive 
T cells (27-29). In this regard, it is worth noting that only 
DCs but not PBMCs could activate cord blood T cells. This 
finding reinforces the notion that DCs are the only cells capable 
of triggering naive T  cells and is an apparent contrast with 
a report that adult CD45RA + naive T  cells can be stimu- 
lated by allogeneic PBMCs (30). It is possible, however, that 
either cord blood cells have higher requirements for costimu- 
lation than adult T cells, or that the alloreactive response by 
adult CD45RA + T cells may involve memory cells that have 
reverted to  the CD45RA + phenotype, but  retain the ca- 
pacity to respond to nonprofessional or semiprofessional APCs 
(31,  32). 
Presentation of soluble antigen by DCs has been reported 
to be rather inefficient in the sense that relatively high con- 
centrations of antigen were required (10 -6  and  10 -7 M), 
comparable to those required by other nonantigen-specific 
APCs (4,  9-11).  In contrast, we found that DCs cultured 
with GM-CSF  +  IL-4 can present TT at concentrations of 
10-10 M  and are therefore 100-300-fold more efficient than 
nonspecific B cells or PBMCs. These DCs are actually com- 
parable to antigen-specific B cells, which can use membrane 
Ig for antigen capture. Furthermore, in the presence of im- 
mune  complexes,  DCs  become  even more  efficient than 
antigen-specific B cells, being able to present TT at the ex- 
traordinary low concentration of 10-12 M. This is the most 
efficient presentation of soluble antigen reported to date. 
This highly efficient presentation of soluble antigen de- 
pends on the preservation of the immature phenotype, since 
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is thus possible that the antigen-presenting capacity of DCs 
has been previously underestimated because the immature 
FeyK  + cells may have been lost or induced to mature during 
the isolation procedure. 
Several mechanisms may contribute to the eificient antigen 
presentation of DCs: first, their capacity for clustering T cells 
in an antigen-independent fashion (33);  second, the expres- 
sion of high levels of MHC molecules, allowing presenta- 
tion of more T cell determinants; third, the high expression 
of adhesion and costimulatory molecules and the low surface 
charge (34, 35), which may lower the number of determinants 
required for T cell activation (36, 37); and fourth, the high 
level of fluid-phase pinocytosis (7) and the expression of func- 
tional Fc'yR (11, 38). 
A striking finding is the response of DCs to TNF-ol and 
CD40L.  Within 24 h, surface expression of MHC class II, 
ICAM-1, LFA-3, CD40, and B7 increases two- to threefold, 
whereas expression of Ii and FcyRII decreases. The functional 
consequences are an increased T cell stimulatory capacity in 
MLK, but a 10-fold decrease in presentation of soluble TT 
and a 100-fold decrease in presentation of TT-IgG complexes. 
The effect on class II molecules and Ii is of particular interest. 
Preliminary experiments indicate that the increase in surface 
class II expression is not accompanied by an increase in class 
II biosynthesis, suggesting an effect of TNF-o~ at the post- 
translational level. Indeed, staining for intracellular class II 
molecules revealed  that TNF-cx induces a rapid disappear- 
ance of class II containing structures that are prominent in 
immature DCs and a redistribution of class II molecules to- 
wards the cell periphery (SaUusto, F., unpublished results). 
Thus, there are differences in the mechanism that lead to down- 
regulation of antigen presenting capacity in cultured DCs 
and in fresh LCs.  Whereas in both cases Fc~RII is down- 
regulated, a downregulation of dass II synthesis is observed 
only in LCs (39,  40).  Further work is required to identify 
the level of this regulation and the signals involved (41, 42). 
It is interesting to discuss our results in the context of the 
well known maturation pathway of LCs. It has been shown 
that LCs form a reservoir of immature DCs that, upon anti- 
genic stimulation, resume their migratory behavior and move 
to the draining lymph nodes, where they arrive as mature 
DCs (1, 43). A similar maturation process is known to occur 
spontaneously when these cells are cultured in vitro (4). On 
the basis of our results it is interesting to hypothesize that 
TNF-c~ may play a physiological role in vivo in the induc- 
tion of migration and maturation (44, 45). Local production 
of TNF-ot at sites of encounter with "infectious" antigen 
(46) may induce maturation of DCs and their migration from 
tissues into secondary lymphoid organs. It is interesting to 
note that TNF-c~ induces the appearance of a CD44 isoform 
carrying the v9 exon, which may be involved in controlling 
migratory behavior (47). The role of CD40L may be limited 
to a later stage,  when DC localize in T-dependent areas of 
lymph nodes. 
Whereas local production of TNF-ot may play a physio- 
logical role in regulating antigen presentation by DCs, high 
systemic levels of TNF-o~, such as in malignancies or chronic 
inflammatory diseases, may be detrimental (48).  Too much 
TNF-ot may cause generalized immunosuppression by in- 
ducing all DCs to mature and lose the capacity to present 
new incoming antigens. 
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